Brachyury is a transcription factor of the T-box family typically expressed in notochord and chordoma. Some studies report brachyury as highly specific for chordoma, whereas others have concluded that brachyury is expressed in many types of common carcinomas by reverse transcription polymerase chain reaction and immunohistochemistry and could be involved in the epithelial-mesenchymal transition and metastatic process. In this study, we immunohistochemically evaluated 5229 different tumors for nuclear brachyury expression using a new rabbit monoclonal antibody and automated immunostaining (Leica Bond Max). Only nuclear labeling was scored, and antibody dilution of 1:2000 was used. In normal tissues, only rare cells in seminiferous tubules were labeled; all other organs were negative. All chordomas (75/76), except a sarcomatous one, were positive, whereas chondrosarcomas were negative. Among epithelial tumors, positivity was often detected in embryonal carcinoma (74%) and seminoma (45%). Pulmonary small cell carcinoma was often positive (41%), whereas pulmonary and pancreatic adenocarcinomas only rarely showed nuclear brachyury positivity (3% to 4%). Common carcinomas such as ductal carcinomas of the breast or adenocarcinomas of the prostate only exceptionally showed nuclear positivity (< 1%). No colorectal, hepatocellular, renal cell, squamous cell, thyroid or urothelial carcinoma, or mesothelioma showed nuclear brachyury positivity. Among mesenchymal and neuroectodermal tumors, only isolated cases of melanoma, malignant peripheral nerve sheath tumor, rhabdomyosarcoma, synovial sarcoma, and follicular lymphoma showed nuclear expression. However, as shown previously with lung carcinoma, experiments with lower antibody dilutions (1:200 to 1:500) showed weak cytoplasmic and nuclear labeling in breast cancers. In addition to chordoma, we show here for the first time that nu-clear brachyury expression is prevalent in embryonal carcinoma, seminoma, and small cell carcinoma of the lung but very rare in common carcinomas, sarcomas, and melanoma. With these From the reservations, we have demonstrated the presence of nuclear brachyury immunoreactivity to be a sensitive and fairly specific marker for chordoma. FIGURE 2. Nuclear brachyury expression in germ cell tumors. A, Seminoma commonly showing nuclear positivity. B, Embryoid body in embryonal carcinoma and rare cells outside it are positive. C, Embryonal carcinoma with a strongly positive area showing brachyury expression. D, Yolk sac tumor with focal positivity. Miettinen et al Am
T he brachyury gene ("short tail" from Greek, also designated as "T gene") encodes a transcription factor in the T-box group of morphogenetic genes and has homologous forms in mice and humans. 1, 2 The encoded brachyury protein is important in the development of the posterior and caudal body elements including the notochord of mice. Although initially expressed in subsets of primitive epithelial and mesenchymal cells, in adult tissues brachyury is almost exclusively expressed in the notochord. [3] [4] [5] [6] In animals, loss-of-function mutations cause defects in the tail development 2 ; in humans, germline gene duplications have been associated with familial chordoma, and similar somatic changes have been associated with sporadic chordoma. 7, 8 Nuclear expression of brachyury protein has been immunohistochemically detected in notochord and their neoplastic counterpart, chordomas. 9 In 1 study, chordomas showed strong nuclear brachyury expression, whereas brachyury was absent in other types of tumors, including carcinomas, sarcomas, and gliomas. 9 A small number of soft tissue tumors considered extra-axial chordomas were also shown to be brachyury positive. 10, 11 Another study found no immunohistochemically detectable brachyury expression in potential chordoma mimics, such as different types of germ cell tumors and renal cell carcinomas, in contrast to chordoma. 12 These studies used a variety of polyclonal and monoclonal antibodies.
The transcription factor brachyury has been also identified as a driver in the epithelial-mesenchymal transition for several types of carcinomas and is being explored as a target antigen in tumor vaccine studies. 13 Brachyury expression has been detected, among others, in mammary, 14 pulmonary, 15, 16 prostatic, 17 and colorectal carcinomas 18 and is often associated with aggressive disease and poor prognosis. In those studies, brachyury has been detected by reverse transcription polymerase chain reaction and immunohistochemistry, finding both nuclear and cytoplasmic expression. Human T cells generated against brachyury peptide were shown to lyse a range of carcinomas including those of breast, lung, and colon. 13 In addition, immunohistochemical studies demonstrated nuclear brachyury expression in oral squamous cell carcinoma, finding it associated with the development of lymph node metastases. 19 In cancer biology, brachyury has also been linked with epithelial-mesenchymal transition leading into a more invasive phenotype of tumors. 20 Previous immunohistochemical studies have reported high specificity of brachyury for chordoma versus carcinomas, 9 whereas several other studies reported widespread expression of brachyury in various carcinomas [14] [15] [16] [17] [18] [19] ; these studies seem to contradict each other but may be explained by differences in technique, antibody, or definition of expression. In this study, we utilized a newly developed rabbit monoclonal antibody (MAb) to examine nuclear brachyury expression in >5000 human tumors, including chordoma and its mimics, and a wide variety of carcinomas, sarcomas, and melanomas. Our aim was to examine the specificity of this antibody to chordoma and reveal its other diagnostic potential using exclusive scoring of nuclear labeling.
MATERIALS AND METHODS
Large numbers of chordomas, chondrosarcomas, and other tumors relevant in the differential diagnosis of chordoma, and other epithelial, mesenchymal, neuroectodermal, and lymphohematopoietic tumors, were organized in multitumor blocks containing 30 to 70 different cases each. The size of each sample exceeded the size of a 0.6 mm 2 microarray core by a factor of at least 5 to 15. Normal adult and fetal human tissues were also studied. All tissues were derived from anonymized surgical specimens.
The previously described primary rabbit MAb (MAb 54-1, IgG1 isotype) was raised to brachyury protein and was predicted to recognize a carboxyterminal epitope. 21 This antibody reacted with a 49 kD protein by immunoblotting, and immunoblotting reactivity was absent in cells in which the brachyury gene was silenced by RNA interference. The antibody did not react with other T-box proteins during in vitro testing. 21 Immunohistochemical staining was performed in a Leica Bond Max automated system (Leica, Bannockburn, IL) using the Leica-Refine detection kit. Immunostaining was preceded by Leica high-pH epitope retrieval for 25 minutes. The primary antibody was diluted 1:2000, corresponding to antibody concentration of 0.6 mg/mL. The primary antibody was incubated for 30 minutes, followed by the Leica polymer and postpolymer for 15 min each, DAB for 10 minutes, and a hematoxylin counterstain for 5 minutes. A chordoma or brachyurypositive seminoma was used as a positive control.
Cytoplasmic staining was generally rare with the antibody dilution used and was not scored. However, if a lower dilution of primary antibody was used (1:200 to 1:500), a variably weak cytoplasmic and nuclear labeling was obtained in a multitumor block containing ductal carcinomas of the breast.
RESULTS
All results presented here were obtained with a 1:2000 dilution of the primary antibody, following the methods described above.
Normal Fetal and Adult Tissues
Fetal tissues (10 wk) did not show nuclear brachyury immunoreactivity in the skin, paraspinal, and limb soft tissues, liver, intestines, or kidney. However, notochord elements were not available for observation. None of the normal adult tissues examined, including skin, gastrointestinal tract, liver, pancreas, lung, endometrium, prostate, thyroid, and lymphoid tissue of the tonsil, showed any nuclear immunoreactivity. However, scattered cells in seminiferous tubules variably showed brachyury-positive nuclei.
Chordoma, Chondrosarcoma, and Mixed Tumors/Myoepitheliomas
The results on epithelial tumors have been summarized in Table 1 . All chordomas except 1 case with spindle cell sarcomatous transformation showed nuclear brachyury expression ( Fig. 1A) . In addition, variable cytoplasmic staining was observed. In contrast, none of the chondrosarcomas of the bone were positive (Table 2 ). However, these tumors showed variable cytoplasmic labeling (Fig. 1B) . All extraskeletal myxoid chondrosarcomas were also negative. Although none of the 131 mixed tumors/ myoepitheliomas of the salivary gland showed nuclear positivity, 2 cutaneous or soft tissue examples showed nuclear positivity (Figs. 1C, D) . One of these tumors contained p63-positive cells as expected of tumors with myoepithelial differentiation. All renal cell carcinomas were negative.
Other Epithelial Neoplasms
In general, nuclear brachyury expression was rare in other epithelial neoplasms but occurred often in germ cell tumors, small cell carcinomas, and very occasionally in common carcinomas (Table 1) .
Among germ cell tumors, 46% of seminomas showed typically uniform nuclear labeling ( Fig. 2A) , whereas the other cases were negative. Embryonal carcinomas (74%) often showed focal positivity in a minority of tumor cells, typically <10% to 20% (Figs. 2B, C) . Endodermal sinus tumors also showed focal positivity (Fig. 2D ). Choriocarcinomas or components with trophoblastic differentiation were negative.
Small cell carcinoma of the lung was the most frequently positive non-germ cell tumor (41%). In these cases, 10% to 30% of tumor cells showed nuclear labeling (Fig. 3A) . Other pulmonary carcinomas were only rarely positive. These included 9/212 (4%) pulmonary adenocarcinomas, which usually showed very focal labeling (range: 1% to 15%, median 3%). Some usual acinar adenocarcinomas also showed focal positivity (Figs. 3B, C) . Multifocal strong nuclear brachyury was seen in 1 so-called embryonal carcinoma of the lung, a tumor showing glands resembling secretory endometrium (Fig. 3D) .
When using a 1:2000 dilution of the MAb, only 1/ 427 ductal carcinomas of the breast (< 1%) showed nuclear brachyury expression, which was focal and seen in 10% of tumor cells (Fig. 4A ). This carcinoma was ER/ PR+, Her2 2+, without basal cell phenotype (negative for CK5/6 and Trim29). However, if a lower dilution of primary antibody was used (1:200 to 1:500), a variably weak cytoplasmic and nuclear labeling was obtained in a multitumor block containing ductal carcinomas of the breast. Only 1 prostatic adenocarcinoma (0.5%) had nuclear brachyury labeling, which was focal. This case had Gleason score 5+4 features and contained nuclear brachyury labeling in 30% of tumor cells (Fig. 4B ). Three pancreatic adenocarcinomas (3%) showed focal positivity (< 10% of tumor cells). The sole endometrial carcinoma (1/236) with nuclear brachyury was a high-grade carcinoma with a solid nonglandular pattern (Fig. 4C) showing low estrogen receptor expression (10% of tumor cells), MSH2/MSH6 mismatch-repair deficiency status, and focal nuclear b-catenin expression. One endometrioid carcinoma of the ovary was also positive (Fig. 4D ).
All adrenocortical, colorectal, hepatocellular, renal, thyroid, ovarian serous, and clear cell carcinomas were negative for nuclear brachyury labeling. None of the squamous carcinomas of the skin, head and neck, or lung showed nuclear brachyury positivity.
Mesenchymal, Neuroectodermal, and Lymphoid Neoplasms
In malignant mesenchymal and neuroectodermal tumors, nuclear brachyury expression was distinctly rare and seen in only 1 each of metastatic melanoma (Fig. 5A) , high-grade malignant peripheral nerve sheath tumor (Fig. 5B ), Ewing sarcoma (Fig. 5C ), monophasic synovial sarcoma (Fig. 5D ), and embryonal rhabdomyosarcoma. In these cases, 5% to 10% of tumor cells were positive. Lymphomas (45 diffuse large B cell, 24 small lymphocytic, 26 follicular, 20 T cell, miscellaneous) were negative, except 1 follicular lymphoma that showed brachyury positivity in approximately 10% of nuclei.
DISCUSSION
In this study, we examined immunohistochemically detectable nuclear brachyury expression in chordomas and a wide variety of epithelial, mesenchymal, neuroectodermal, and lymphohematopoietic neoplasms, to further explore the distribution of brachyury in human tumors, and the potential specificity of brachyury for chordoma. To our knowledge, we are the first to observe frequent nuclear brachyury positivity in germ cell tumors and small cell carcinomas of the lung.
Our findings confirm the observations that nuclear brachyury is consistently expressed in chordoma. [9] [10] [11] [12] The only exceptions seem to be inconsistent or absent expression in chordomas that have undergone sarcomatoid transformation. Furthermore, there is a strong contrast between chordoma and chondrosarcoma, including extraskeletal myxoid chondrosarcoma, as these tumors lack nuclear brachyury expression. Rare examples of soft tissue mixed tumor/myoepitheliomas expressed brachyury. Some of these tumors may be similar to tumors reported as peripheral (extra-axial) counterparts of chordomas, as previously described and found to be brachyury positive. [10] [11] However, in these cases, it is advisable to rule out the possibility of chordoma metastatic into soft tissues.
Unlike chordomas, only a few types of epithelial neoplasms demonstrated significant nuclear brachyury expression with the specific dilution of rabbit antibrachyury MAb (1:2000) and technique reported here, including germ cell tumors and pulmonary small cell carcinomas. Among germ cell tumors, testicular seminomas commonly show extensive brachyury expression. We could not determine how the positive and negative cases differ. In embryonal carcinoma, brachyury expression is typically restricted to focal areas. A previous study with a different antibody found that all germ cell tumors were negative. However, studies on embryonal carcinoma cell lines have detected brachyury expression. 22, 23 Therefore, brachyury expression in germ cell tumors may reflect phenotypic similarity to early embryonic tissues. Additional studies are warranted to examine the possible clinical significance of brachyury expression.
Small cell carcinomas also showed a high frequency of positivity for brachyury nuclear expression. However, common carcinomas of breast, prostate, lung, and endometrium only exceptionally showed nuclear positivity, further indicating that nuclear brachyury positivity is fairly specific for chordoma when facing the differential diagnosis of chordoma versus common carcinomas. However, numerous studies have found brachyury expression in carcinomas, and many have indicated that brachyury is associated with poor prognosis. Those studies [14] [15] [16] [17] [18] [19] have variably detected brachyury transcripts by reverse transcription polymerase chain reaction, but also by immunohistochemistry, and nuclear positivity along with cytoplasmic positivity have been reported.
However, all these studies used other antibodies or a lower dilution of the rabbit MAb. 21 The uniqueness and high degree of specificity of the anti-brachyury rabbit MAb used here, in comparison with other commercially available antibodies, has been previously shown in enzyme-linked immunosorbent assay and western blot analyses. 21 It therefore seems that the rabbit MAb we used is exceptionally specific for chordoma versus carcinoma, when using a high antibody dilution (1:2000) . Lower antibody dilutions result in variably weak cytoplasmic and nuclear labeling in other tumors, such as breast and lung carcinomas. 21 In conclusion, nuclear brachyury expression, as tested with a new rabbit MAb, is relatively specific for chordoma and is not expressed in chondrosarcoma and other sarcomas, with few exceptions. Occasional soft tissue myoepitheliomas can express brachyury and may represent peripheral counterparts of chordoma. Among epithelial neoplasms other than chordomas, embryonal carcinomas and seminomas and small cell carcinomas frequently express nuclear brachyury, whereas the common carcinomas very rarely do, when tested with the conditions reported here. With these reservations, we have demonstrated the presence of nuclear brachyury immunoreactivity to be a sensitive and fairly specific marker for chordoma. Potential brachyury expression in nonchordomas has to be considered in diagnostic practice.
